Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 16/20 | 0.64 |
| ▸ | HDAC8 | Q9BY41 | 12/20 | 0.64 |
| ▸ | HDAC2 | Q92769 | 13/20 | 0.56 |
| ▸ | HDAC3 | O15379 | 11/20 | 0.56 |
| ▸ | HDAC6 | Q9UBN7 | 11/20 | 0.56 |
| ▸ | HDAC4 | P56524 | 10/20 | 0.56 |
| ▸ | HDAC7 | Q8WUI4 | 9/20 | 0.56 |
| ▸ | HDAC10 | Q969S8 | 9/20 | 0.56 |
| ▸ | HDAC11 | Q96DB2 | 9/20 | 0.56 |
| ▸ | HDAC9 | Q9UKV0 | 9/20 | 0.56 |
| ▸ | HDAC5 | Q9UQL6 | 9/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.49 |
| ▸ | LMNA | P02545 | 3/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7832354 | 1.00 | HDAC1 (0.64) | HDAC1HDAC8HDAC2HDAC3HDAC6 | |
| SCHEMBL7832648 | 1.00 | HDAC1 (0.64) | HDAC1HDAC8HDAC2HDAC3HDAC6 | |
| SCHEMBL7831099 | 0.96 | HDAC1 (0.58) | HDAC1HDAC8HDAC2HDAC3HDAC6 | |
| SCHEMBL7831097 | 0.96 | HDAC1 (0.58) | HDAC1HDAC8HDAC2HDAC3HDAC6 | |
| SCHEMBL7832237 | 0.85 | CYSLTR2 (0.59) | HDAC1HDAC8HDAC2HDAC3HDAC6 | |
| SCHEMBL7832861 | 0.85 | CYSLTR2 (0.59) | HDAC1HDAC8HDAC2HDAC3HDAC6 | |
| SCHEMBL7832243 | 0.85 | CYSLTR2 (0.59) | HDAC1HDAC8HDAC2HDAC3HDAC6 | |
| SCHEMBL7820491 | 0.81 | CYSLTR2 (0.60) | HDAC1HDAC8HDAC2HDAC3HDAC6 | |
| SCHEMBL7820483 | 0.81 | CYSLTR2 (0.60) | HDAC1HDAC8HDAC2HDAC3HDAC6 | |
| SCHEMBL8650189 | 0.81 | CYSLTR2 (0.55) | HDAC1HDAC8HDAC2HDAC3HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0737671-B1 | Aromatic hydroxamic acid compounds, their production and use | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2001-12-12 | — | — | EP | claimed |
| US-8071620-B2 | Carbamic acid compounds comprising a bicyclic heteroaryl group as HDAC inhibitors | TOPOTARGET UK LIMITED (GB) | 2011-12-06 | — | — | US | disclosed |
| US-8071620-B2 | Carbamic acid compounds comprising a bicyclic heteroaryl group as HDAC inhibitors | TOPOTARGET UK LIMITED (GB) | 2011-12-06 | — | — | US | disclosed |
| US-20100093743-A1 | CARBAMIC ACID COMPOUNDS COMPRISING A BICYCLIC HETEROARYL GROUP AS HDAC INHIBITORS | TOPOTARGET UK LIMITED (GB) | 2010-04-15 | — | — | US | disclosed |
| US-20100093743-A1 | CARBAMIC ACID COMPOUNDS COMPRISING A BICYCLIC HETEROARYL GROUP AS HDAC INHIBITORS | TOPOTARGET UK LIMITED (GB) | 2010-04-15 | — | — | US | disclosed |
| US-7652036-B2 | Carbamic acid compounds comprising a bicyclic heteroaryl group as HDAC inhibitors | TOPOTARGET UK LIMITED (GB) | 2010-01-26 | — | — | US | disclosed |
| US-7652036-B2 | Carbamic acid compounds comprising a bicyclic heteroaryl group as HDAC inhibitors | TOPOTARGET UK LIMITED (GB) | 2010-01-26 | — | — | US | disclosed |
| EP-0737671-B1 | Aromatic hydroxamic acid compounds, their production and use | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2001-12-12 | — | — | EP | disclosed |
| US-5804601-A | USEFUL FOR TREATING ALZHEIMER'S DISEASE, MULTIPLE SCLEROSIS, BACTERIAL OR VIRAL MENINGITIS, DOWN'S SYNDROME AND PARKINSON'S DISEASE | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1998-09-08 | — | — | US | disclosed |
| EP-0737671-A2 | Aromatic hydroxamic acid compounds, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1996-10-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093743-A1 | CARBAMIC ACID COMPOUNDS COMPRISING A BICYCLIC HETEROARYL GROUP AS HDAC INHIBITORS | HDAC1, HDAC7, HDAC5 | HDAC1 1/4885HDAC8 4/4885HDAC2 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.